← Back to All US Stocks

Genenta Science S.p.A. (GNTA) Fundamental Analysis & AI Grade 2026

GNTA Nasdaq Biological Products, (No Diagnostic Substances) L6 CIK: 0001838716
Recently Updated • Analysis: May 28, 2026 • SEC Data: 2026-05-28

Genenta Science S.p.A. (GNTA) Financial Metrics & Key Ratios

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

GNTA Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

GNTA vs Healthcare Sector: How Genenta Science S.p.A. Compares

How Genenta Science S.p.A. compares to Healthcare sector averages

Net Margin
GNTA 0.0%
vs
Sector Avg 12.0%
GNTA Sector
ROE
GNTA 0.0%
vs
Sector Avg 15.0%
GNTA Sector
Current Ratio
GNTA 0.0x
vs
Sector Avg 2.0x
GNTA Sector
Debt/Equity
GNTA 0.0x
vs
Sector Avg 0.6x
GNTA Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is Genenta Science S.p.A. Stock Overvalued? GNTA Valuation Analysis 2026

Based on fundamental analysis, Genenta Science S.p.A. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

Genenta Science S.p.A. Balance Sheet: GNTA Debt, Cash & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

GNTA Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

GNTA SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for Genenta Science S.p.A. (CIK: 0001838716)

📋 Recent SEC Filings

Date Form Document Action
May 5, 2026 4 xslF345X06/ownership.xml View →
Apr 1, 2026 4 xslF345X06/ownership.xml View →
Apr 1, 2026 4 xslF345X06/ownership.xml View →
Apr 1, 2026 4 xslF345X06/ownership.xml View →
Apr 1, 2026 4 xslF345X06/ownership.xml View →

Frequently Asked Questions about GNTA

What is the AI rating for GNTA?

Genenta Science S.p.A. (GNTA) has an AI grade of N/A with 0% confidence, based on fundamental analysis of SEC EDGAR filings.

What are GNTA's key strengths?

Claude: Analysis in progress.

What are the risks of investing in GNTA?

Claude: Analysis in progress.

What is GNTA's revenue and growth?

Genenta Science S.p.A. reported revenue of N/A.

Does GNTA pay dividends?

Genenta Science S.p.A. does not currently pay dividends.

Where can I find GNTA SEC filings?

Official SEC filings for Genenta Science S.p.A. (CIK: 0001838716) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is GNTA's EPS?

Genenta Science S.p.A. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.

What is GNTA's fundamental grade?

Based on our AI fundamental analysis in May 2026, Genenta Science S.p.A. has a N/A grade with 0% confidence. Review the strengths and risks sections above for full context. This is not investment advice.

Is GNTA stock overvalued or undervalued?

Valuation metrics for GNTA: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

What is GNTA's AI grade for 2026?

Our dual AI analysis gives Genenta Science S.p.A. a combined N/A grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is GNTA's free cash flow?

Genenta Science S.p.A.'s operating cash flow is N/A, with capital expenditures of N/A.

How does GNTA compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).

Top Rated Stocks
AAPL 92% MSFT 92% FAST 92% ANET 88% RDDT 88% KNSL 88% MGRE 88% FIZZ 88% DECK 87% NVDA 87%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: May 28, 2026 | Data as of: 2026-05-28 | Powered by Claude AI